Abstract: Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.
April 15, 1993
Date of Patent:
December 16, 1997
The United States of America as represented by the Department of Health and Human Services